Boundless Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 101
- Market Cap
- $84.7M
- Website
- http://www.boundlessbio.com
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Boundless Bio
- Target Recruit Count
- 42
- Registration Number
- NCT06299761
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Boundless Bio
- Target Recruit Count
- 150
- Registration Number
- NCT05827614
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Sarcoma Oncology, Santa Monica, California, United States
© Copyright 2024. All Rights Reserved by MedPath